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2002, detailed demographic and survival information were obtained. A 
total of 18346 (70%)documented smokers including the former and the 
current and 7755(30%) documented never smokers with non-small cell 
lung cancer were studied. Among them, the 2546 patients with stage IV 
lung adenocarcinoma were studied to examine the relationship between 
the smoking status or the gender and the chemotherapy effect. Multi-
variate analysis was performed using the Cox regression method.
Results: There was an increased percentage of female subjects (72%) 
in the never smokers, and an increased percentage of male subjects 
(90%) in the smokers. The never smokers had lower performance 
status (PS) and lower clinical stage than the smokers (p<0.001). There 
was an increased percentage of adenocarcinoma (83%) in the never 
smokers. Multivariate analysis for all the patients demonstrated that 
the lower clinical stage, the lower PS, younger age, female and never 
smoking was an independent good prognostic factor The hazard ratio 
(HR) and its 95%CI was 3.73(3.58-3.88),2.69(2.59-2.79), 1.21(1.17-
1.25), 1.15(1.09-1.20), and 1.08(1.04-1.14), respectively. Multivariate 
analysis for the stage IV adenocarcinoma also showed that the lower 
PS, female and never smoking was an independent good prognostic 
factor. The HR and its 95%CI was 2.37(2.15-2.61), 1.35(1.19-1.52) 
and 1.17(1.04-1.32) respectively. In the treatment of chemotherapy for 
the stage IV adenocarcinoma patients, the never smokers had higher 
disease control rates (CR+PR+SD) than the smokers (p=0.08) and the 
females had higher response rates (CR+PR) than the males (p=0.02).
Conclusions: The never smokers and females with non-small cell lung 
cancer were found to have a distinct and improved clinical outcome.
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Background: In order to describe the recent lung cancer incidence & 
mortality in Taiwan, a Bayesian age-period-cohort (APC) model was 
applied 
Methods: Using the National Cancer Registry data from 1979 to 2002 
(n=91811), data from 1996 to 2002 with age at diagnosis between 20 
to 89 years old were used (n=44139) in view of data completeness 
(survival status & treatment strategies). An autoregressive prior model 
was used to smooth age, period, and cohort effects. Posterior distribu-
tions were derived from 5,000 iterations to draw inferences & 95% 
conﬁdence interval (95%CI). We deﬁned the median iterated value 
as an overall summary data. Age-adjusted standardized mortality & 
incidence rate (ASMR & ASIR, per 100000 person-year) and case 
fatality rate (ASMR/ASIR) were calculated using population in 2002 
as reference. Descriptive analysis was done for periodical treatment 
strategies distribution (operation, chemotherapy, & others) and related 
case fatality rate. 
Results: The mid-term mortality (2 year ASMR) was decreasing for 
male lung cancer patients in Taiwan since around year 2000 (from 48 
in 2000 to 45 in 2002), which was mainly due to decrease in incidence 
(ASIR) during this period (from 61 in 2000 to 57 in 2002). As for 
female, the mid-term (2 year) mortality was still slightly increasing 
(from 19 in 1996 to 22 in 2002), which was mainly due to increasing 
incidence (from 24 in 1996 to 29 in 2002). There were small improve-
ment in short term (1 year) case fatality rate, possibly due to Increased 
utilization (about 15~18% increment) of chemotherapy. The improve-
ment ranged from 68% (95%CI: 65-71) in 1997 to 65% (63-68) in 
2002 for male (ﬁg 1, upper) and 63% (59-67) in 1996 to 57% (54-60) 
in 2002 for female (ﬁg 1, lower). However, the mid term (2 year) case 
fatality rate roughly remained the same, especially for male (81% (95% 
CI 78-84) in 1997 to 82% (79-84) in 2002) (ﬁg 1, upper) in contrast to 
female (78%(74-83) in 1997 to 75(72-79) in 2002) (ﬁg 1, lower)
Conclusions: Mid-term mortality was decreasing for male lung cancer 
patients in Taiwan since around year 2000, while it was slightly increas-
ing for female. These changes were mainly due to change in incidence 
during this period. Increased utilization of chemotherapy may lead to 
small improvement in short term instead of mid term case fatality rate.
Figure 1. 1y: one year; 2y: two year; E: estimated case fatality rate; L & H: 95 % 
confidence interval
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Background: Certain racial minorities exhibit poor survival in early 
stage non-small cell lung cancer (NSCLC) in the US and is generally 
attributed to low socioeconomic status (SES). We investigated how the 
role SES may play a role in this disparity in survival.
Methods: We conducted a case-only analysis of the California Cancer 
Registry (CCR) (1989-2003) including descriptive analysis of relevant 
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clinical variables and SES. The SES variable was derived from prin-
ciple component analysis of census block level CCR data linked to cen-
sus data addressing seven major indicators of SES and is divided into 
ﬁve quintiles. Univariate survival analyses were conducted using the 
Kaplan-Meier method. Multivariate survival analyses were performed 
using Cox proportional hazards ratios.
Results: 19,702 incident cases of stage I NSCLC were analyzed. 
Low SES was found in a greater proportion of African-American and 
Hispanic patients, and was signiﬁcantly associated with more males, 
unmarried patients, IB disease, squamous cell histology, poorly-differ-
entiated tumors, fewer surgical resections performed, and less overall 
treatment received. Reasons for no surgery were primarily associated 
with low SES and unmarried status. In multivariate analysis, unmarried 
status carried an independent increased risk of mortality (vs. married; 
HR = 1.18, 95% CI = 1.12 to 1.23). Low SES was also identiﬁed to 
independently carry increased mortality risk. Each incremental increase 
in SES quintile was associated with statistically signiﬁcant decrease 
hazard of death (SES 2 vs. SES1, HR = 0.91, 95%CI = 0.85 to 0.98; 
SES3 vs. SES 1, HR = 0.90, 95% CI = 0.84 to 0.97; SES4 vs. SES1, 
HR = 0.83, 95% CI = 0.77 to 0.89; SES5 vs. SES1, HR = 0.78, 95% CI 
= 0.72 to 0.84). African-American race was not an independent poor 
prognostic factor for survival after adjustment for SES or marital status 
while Hispanic race was not an independent poor prognostic factor 
after adjustment for surgical treatment.
Conclusion: Low SES is an independent poor prognostic factor for 
survival in stage I NSCLC, and is independent of race, marital status, 
surgery and other poor prognostic factors. Mitigating the effects of low 
SES will likely improve early stage NSCLC survival. 
A=SES1(lowest), B=SES2(low), C=SES3, D=SES4(high), E=SES5(highest)
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Background: In high-risk subjects low-dose sCT initially showed a 4-
fold increase in the detection rate of neoplastic nodules in comparison 
with chest-X-ray. However, two recent papers (I-ELCAP Investigators 
NEJM 2006; 355:1763-1771 and Bach PB et al. JAMA 2007; 297:953-
961) led to controversial results about the efﬁcacy of sCT in improving 
overall survival of lung cancer and in addition no information about 
mortality reduction are still available from any randomized trial. Sub-
jects and Methods: From April to December 2001, 520 asymptomatic 
volunteers aged ≥ 55 years with a history of cigarette smoking ≥ 20 
packs-year and of no previous cancer received annually chest sCT for 5 
consecutive years. 
Results: At baseline 73% were male, median age was 59 years and 
91% current smokers. At baseline sCT 127 subjects (24.5%) had nod-
ules <5 mm while nodules ≥5 mm were detected in 114 (22%); the size 
of lung nodules ranged from 5 to 9.9 mm in 81.5% of the cases. The % 
of nodules worth of additional investigation varied over time (2nd yr: 
6%; 3rd yr: 5%; 4th yr: 11%; 5th yr: 11%). Five (1%) cases of LC were 
detected during the ﬁrst year (3 stage I) and in two additional resec-
tions an atypical adenomatous hyperplasia was found. Three new cases 
of thoracic cancers were detected in the second and third year. In the 
fourth year, ﬁve lung cancer (one unresectable stage IIIB) and a thymic 
carcinoma were detected. In the ﬁfth year 4 new cases (2 surgically 
resected) and a renal cancer were diagnosed. One interval case was 
detected during the third year. Following the end of the study two new 
cancers were detected (both negative for nodules at the last screening 
sCT), one resected (squamous carcinoma, stage IA, asymptomatic) and 
a symptomatic limited disease small cell lung cancer. For these 2 cases 
the interval between the last screening sCT and the diagnosis is 16 and 
16.8 months, respectively. Drop-out rate in the ﬁrst year was 25 (2nd yr 
22, 3rd yr 18 and 4th yr 24). During the 5-year screening period 31,5% 
of subjects quit smoking but, of these, 8% started again to smoke dur-
ing the course of the study. As March 2006, 17 out of 25 diagnosed 
cancer are still alive, with only one case (stage IIIA) with progression 
of disease. The median survival time for surgically resected cases who 
already died (n=6, including two cases in pathological stage I) is 25 
months, and 1,6 months for the case of thymic carcinoma (4 deaths 
were cancer related). 
Conclusion: Our study conﬁrmed the potential of sCT in the early 
detection of lung cancer. Evidence from ongoing randomised trials is 
needed to support the routine use of sCT for early detection of LC. A 
program of smoking cessation is strongly recommended for further 
studies. Currently a conservative attitude should be encouraged. 
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Survivin is an apoptosis inhibitor and plays an important role in the 
development and progression of cancer. Polymorphisms in the survivin 
gene may inﬂuence survivin production or activity, thereby modulating 
susceptibility to lung cancer. To test this hypothesis, we screened for 
